TTHX-1114 is under clinical development by Trefoil Therapeutics and currently in Phase I for Persistent Corneal Epithelial Defects. According to GlobalData, Phase I drugs for Persistent Corneal Epithelial Defects does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TTHX-1114 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TTHX-1114 is under development for the treatment of corneal endothelial dystrophies such as Fuchs endothelial corneal dystrophy (FECD), Bullous keratopathy as intracameral injection and corneal epithelial defects as ophthalmic formulation, herpetic keratitis(herpetic keratopathy) and corneal ulcers. TTHX-1114 is an engineered fibroblast growth factor-1. The drug candidate is developed based on eFGF-1 technology. It is administered through ophthalmic (topical) in the form of eye drops.
Trefoil Therapeutics overview
Trefoil Therapeutics is a biotechnology company that focused on leveraging its engineered fibroblast growth factor-1 protein technology platform to develop first-in-class pharmacologic treatments for serious corneal endothelial diseases and epithelial disorders. Trefoil Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of TTHX-1114’s drug-specific PTSR and LoA scores, buy the report here.